FDAnews Drug Daily Bulletin

NORWOOD IMMUNOLOGY COMPLETES MELBOURNE BMT CLINICAL TRIAL

July 6, 2006
A A

Norwood Abbey Ltd advises that its subsidiary Norwood Immunology Limited, the company focussed on the rejuvenation of the immune system, has announced the completion of the Melbourne pilot exploratory clinical study in cancer patients undergoing chemotherapy and bone marrow transplantation (BMT). The study sought to determine whether an LHRH agonist can enhance recovery of T cells, which are essential for immune defence mechanisms. Analysis of the data support the interim results as previously announced at the American Hematology Society conference in December 2003.
Business Wire